Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors
Brief Summary: This is an open-label Phase 1b/2 trial of lenvatinib (E7080) plus pembrolizumab in participants with selected solid tumors. Phase 1b will determine and confirm the maximum tolerated dose (MTD) for lenvatinib in combination with 200 milligrams (mg) (intravenous \[IV\], every 3 weeks \[Q3W\]) pembrolizumab in participants with selected solid tumors (i.e. non-small cell lung cancer, renal cell carcinoma, endometrial carcinoma, urothelial carcinoma, squamous cell carcinoma of the head and neck, melanoma or leiomyosarcoma). Phase 2 (Expansion) will evaluate the safety and efficacy of the combination in 7 cohorts at the MTD from Phase 1b (lenvatinib 20 mg/day orally + pembrolizumab 200 mg Q3W, IV).


Options:
A: Arm Label: Arm A (bevacizumab); Type: ACTIVE_COMPARATOR; Interventions: Biological: Bevacizumab, Other: Laboratory Biomarker Analysis, Other: Pharmacological Study | Arm Label: Arm B (bevacizumab and temsirolimus); Type: EXPERIMENTAL; Interventions: Biological: Bevacizumab, Other: Laboratory Biomarker Analysis, Other: Pharmacological Study, Drug: Temsirolimus | Arm Label: Arm C (bevacizumab and sorafenib tosylate); Type: EXPERIMENTAL; Interventions: Biological: Bevacizumab, Other: Laboratory Biomarker Analysis, Other: Pharmacological Study, Drug: Sorafenib Tosylate | Arm Label: Arm D (sorafenib tosylate and temsirolimus); Type: EXPERIMENTAL; Interventions: Other: Laboratory Biomarker Analysis, Other: Pharmacological Study, Drug: Sorafenib Tosylate, Drug: Temsirolimus | Intervention Type: BIOLOGICAL; Name: Bevacizumab; Assigned to Arm(s): Arm A (bevacizumab), Arm B (bevacizumab and temsirolimus), Arm C (bevacizumab and sorafenib tosylate) | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): Arm A (bevacizumab), Arm B (bevacizumab and temsirolimus), Arm C (bevacizumab and sorafenib tosylate), Arm D (sorafenib tosylate and temsirolimus) | Intervention Type: OTHER; Name: Pharmacological Study; Assigned to Arm(s): Arm A (bevacizumab), Arm B (bevacizumab and temsirolimus), Arm C (bevacizumab and sorafenib tosylate), Arm D (sorafenib tosylate and temsirolimus) | Intervention Type: DRUG; Name: Sorafenib Tosylate; Assigned to Arm(s): Arm C (bevacizumab and sorafenib tosylate), Arm D (sorafenib tosylate and temsirolimus) | Intervention Type: DRUG; Name: Temsirolimus; Assigned to Arm(s): Arm B (bevacizumab and temsirolimus), Arm D (sorafenib tosylate and temsirolimus)
B: Arm Label: Pazopanib; Type: EXPERIMENTAL; Interventions: Drug: Pazopanib | Arm Label: Sunitinib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sunitinib | Intervention Type: DRUG; Name: Pazopanib; Assigned to Arm(s): Pazopanib | Intervention Type: DRUG; Name: Sunitinib; Assigned to Arm(s): Sunitinib
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Nexavar (Sorafenib), Drug: IL-2 | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Nexavar (Sorafenib) | Intervention Type: DRUG; Name: Nexavar (Sorafenib); Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: IL-2; Assigned to Arm(s): 1
D: Arm Label: Lenvatinib + Pembrolizumab; Type: EXPERIMENTAL; Interventions: Drug: Lenvatinib, Drug: Pembrolizumab | Intervention Type: DRUG; Name: Lenvatinib; Assigned to Arm(s): Lenvatinib + Pembrolizumab | Intervention Type: DRUG; Name: Pembrolizumab; Assigned to Arm(s): Lenvatinib + Pembrolizumab

Answer: D